{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T11:13:40Z","timestamp":1789298020411,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Produtos Roche Qu\u00edmicos e Farmac\u00eauticos S\/A do Brasil","award":["Produtos Roche Qu\u00edmicos e Farmac\u00eauticos S\/A do Brasil"],"award-info":[{"award-number":["Produtos Roche Qu\u00edmicos e Farmac\u00eauticos S\/A do Brasil"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The economic burden of rare diseases on health systems is still not widely measured, with the generation of accurate information about the costs with medical care for subjects with rare diseases being crucial when defining health policies. Duchenne Muscular Dystrophy (DMD) is the most common form of muscular dystrophy, with new technologies recently being studied for its management. Information about the costs related to the disease in Latin America is scarce, and the objective of this study is to evaluate the annual hospital, home care and transportation costs per patient with DMD treatment in Brazil.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Data from 27 patients were included, the median annual cost per patient was R$ 17,121 (IQR R$ 6,786; 25,621). Home care expenditures accounted for 92% of the total costs, followed by hospital costs (6%) and transportation costs (2%). Medications and loss of family, and patient\u2019s productivity are among the most representative consumption items. When disease worsening due to loss of the ability to walk was incorporated to the analysis, it was shown that wheelchair users account for an incremental cost of 23% compared with non-wheelchair users.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This is an original study in Latin America to measure DMD costs using the micro-costing technique. Generating accurate information about costs is crucial to provide health managers with information that could help establish more sustainable policies when deciding upon rare diseases in emerging countries.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-023-02767-6","type":"journal-article","created":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T22:15:33Z","timestamp":1687472133000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Estimated costs for Duchenne muscular dystrophy care in Brazil"],"prefix":"10.1186","volume":"18","author":[{"given":"Nay\u00ea Balzan","family":"Schneider","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica Caetano","family":"Roos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana L\u00facia Portella","family":"Staub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabela Possebon","family":"Bevilacqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Carolina","family":"de Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tami\u00ea","family":"de Camargo Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia Bergamelli","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla","family":"Loze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas Alex Morales","family":"Saute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Paula Beck da Silva","family":"Etges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carisi Anne","family":"Polanczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,22]]},"reference":[{"key":"2767_CR1","doi-asserted-by":"crossref","unstructured":"Caskey CT, Nussbaum RL, Cohan LC, Pollack L. Sporadic occurrence of Duchenne muscular dystrophy: evidence for new mutation. Clin Genet. 1980 Nov;18(5):329\u201341.","DOI":"10.1111\/j.1399-0004.1980.tb02293.x"},{"key":"2767_CR2","doi-asserted-by":"crossref","unstructured":"Hoffman EP, Brown RHJ, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987 Dec;51(6):919\u201328.","DOI":"10.1016\/0092-8674(87)90579-4"},{"key":"2767_CR3","doi-asserted-by":"crossref","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018 Mar;17(3):251\u201367.","DOI":"10.1016\/S1474-4422(18)30024-3"},{"key":"2767_CR4","doi-asserted-by":"crossref","unstructured":"Crisafulli S, Sultana J, Fontana A, Salvo F, Messina S, Trifir\u00f2 G. Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis. Orphanet J Rare Dis. 2020 Jun;15(1):141.","DOI":"10.1186\/s13023-020-01430-8"},{"issue":"9","key":"2767_CR5","doi-asserted-by":"publisher","first-page":"69591","DOI":"10.34117\/bjdv6n9-416","volume":"6","author":"M Teixeira","year":"2020","unstructured":"Teixeira M, de SR, Martins GMA, Rodrigues JMM, Marques ER. Epidemiologia da distrofia muscular de Duchenne no Cear\u00e1 \/ Epidemiology of Duchenne muscular dystrophy in Cear\u00e1. BJD. 2020;6(9):69591\u2013603.","journal-title":"BJD"},{"key":"2767_CR6","doi-asserted-by":"crossref","unstructured":"de Almeida PAD, Machado-Costa MC, Manzoli GN, Ferreira LS, Rodrigues MCS, Bueno LSM, et al. Genetic profile of brazilian patients with dystrophinopathies. Clin Genet. 2017 Aug;92(2):199\u2013203.","DOI":"10.1111\/cge.12975"},{"key":"2767_CR7","doi-asserted-by":"crossref","unstructured":"Broomfield J, Hill M, Guglieri M, Crowther M, Abrams K. Life Expectancy in Duchenne muscular dystrophy: reproduced individual Patient Data Meta-analysis. Neurology. 2021 Dec;97(23):e2304\u201314.","DOI":"10.1212\/WNL.0000000000012910"},{"key":"2767_CR8","doi-asserted-by":"crossref","unstructured":"Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010 Jan;9(1):77\u201393.","DOI":"10.1016\/S1474-4422(09)70271-6"},{"key":"2767_CR9","unstructured":"Passamano L, Taglia A, Palladino A, Viggiano E, D\u2019Ambrosio P, Scutifero M, et al. Improvement of survival in Duchenne muscular dystrophy: retrospective analysis of 835 patients. Acta Myol. 2012 Oct;31(2):121\u20135."},{"key":"2767_CR10","doi-asserted-by":"crossref","unstructured":"Araujo APQC, de Carvalho AAS, Cavalcanti EBU, Saute JAM, Carvalho E, Fran\u00e7a MCJ, et al. Brazilian consensus on Duchenne muscular dystrophy. Part 1: diagnosis, steroid therapy and perspectives. Arq Neuropsiquiatr. 2017 Aug;75(8):104\u201313.","DOI":"10.1590\/0004-282x20170112"},{"key":"2767_CR11","doi-asserted-by":"crossref","unstructured":"Werneck LC, Lorenzoni PJ, Ducci RDP, Fustes OH, Kay CSK, Scola RH. Duchenne muscular dystrophy: an historical treatment review. Arq Neuropsiquiatr. 2019 Sep;77(8):579\u201389.","DOI":"10.1590\/0004-282x20190088"},{"key":"2767_CR12","first-page":"45","volume-title":"Minist\u00e9rio da Sa\u00fade. Monitoramento do Horizonte Tecnol\u00f3gico: medicamentos para tratamento da distrofia muscular de Duchenne","author":"Brasil","year":"2022","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Monitoramento do Horizonte Tecnol\u00f3gico: medicamentos para tratamento da distrofia muscular de Duchenne. Bras\u00edlia: Minist\u00e9rio da Sa\u00fade; 2022. p. 45."},{"issue":"Suppl 1","key":"2767_CR13","doi-asserted-by":"publisher","first-page":"e000794","DOI":"10.1136\/rmdopen-2018-000794","volume":"4","author":"S Cannizzo","year":"2018","unstructured":"Cannizzo S, Lorenzoni V, Palla I, Pirri S, Trieste L, Triulzi I, et al. Rare diseases under different levels of economic analysis: current activities, challenges and perspectives. RMD Open. 2018;4(Suppl 1):e000794.","journal-title":"RMD Open"},{"key":"2767_CR14","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Secretaria de Ci\u00eancia, Tecnologia, Inova\u00e7\u00e3o e Insumos Estrat\u00e9gicos em Sa\u00fade. Departamento de Gest\u00e3o e Incorpora\u00e7\u00e3o de Tecnologias e Inova\u00e7\u00e3o em Sa\u00fade. Diretriz Metodol\u00f3gica: estudos de microcusteio aplicados a avalia\u00e7\u00f5es econ\u00f4micas em sa\u00fade. 2021. 71p."},{"key":"2767_CR15","doi-asserted-by":"crossref","unstructured":"Keel G, Savage C, Rafiq M, Mazzocato P. Time-driven activity-based costing in health care: a systematic review of the literature. Health Policy. 2017 Jul;121(7):755\u201363.","DOI":"10.1016\/j.healthpol.2017.04.013"},{"key":"2767_CR16","unstructured":"BPS - Banco de Pre\u00e7os em Sa\u00fade. ; V-3.1.33 [Internet]. [cited 10 de junho de 2022]. Available from: http:\/\/bps.saude.gov.br\/"},{"key":"2767_CR17","doi-asserted-by":"crossref","unstructured":"Schreiber-Katz O, Klug C, Thiele S, Schorling E, Zowe J, Reilich P, et al. Comparative cost of illness analysis and assessment of health care burden of Duchenne and Becker muscular dystrophies in Germany. Orphanet J Rare Dis. 2014 Dec;9:210.","DOI":"10.1186\/s13023-014-0210-9"},{"key":"2767_CR18","doi-asserted-by":"crossref","unstructured":"Araujo APQC, Nardes F, Fortes CPDD, Pereira JA, Rebel MF, Dias CM, et al. Brazilian consensus on Duchenne muscular dystrophy. Part 2: rehabilitation and systemic care. Arq Neuropsiquiatr. 2018 Jul;76(7):481\u20139.","DOI":"10.1590\/0004-282x20180062"},{"key":"2767_CR19","doi-asserted-by":"publisher","unstructured":"Garrison S, Kennedy A, Manetto N, Pariser AR, Rutter JL, Yang G. The Economic Burden Of Rare Diseases: Quantifying The Sizeable Collective Burden And Offering Solutions. Health Affairs Forefront. 2022 Feb 01 [cited 2022 May 22]; Available from: https:\/\/www.healthaffairs.org\/do\/https:\/\/doi.org\/10.1377\/forefront.20220128.987667","DOI":"10.1377\/forefront.20220128.987667"},{"key":"2767_CR20","doi-asserted-by":"crossref","unstructured":"Beckers P, Caberg JH, Dideberg V, Dangouloff T, den Dunnen JT, Bours V, et al. Newborn screening of duchenne muscular dystrophy specifically targeting deletions amenable to exon-skipping therapy. Sci Rep. 2021 Feb;11(1):3011.","DOI":"10.1038\/s41598-021-82725-z"},{"key":"2767_CR21","doi-asserted-by":"crossref","unstructured":"Aartsma-Rus A, Krieg AM. FDA approves Eteplirsen for Duchenne muscular dystrophy: the next chapter in the Eteplirsen Saga. Nucleic Acid Ther. 2017 Feb;27(1):1\u20133.","DOI":"10.1089\/nat.2016.0657"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02767-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-023-02767-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02767-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T22:20:23Z","timestamp":1687472423000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-023-02767-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,22]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2767"],"URL":"https:\/\/doi.org\/10.1186\/s13023-023-02767-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2335060\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,22]]},"assertion":[{"value":"13 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Only patients who agreed with the General Personal Data Protection Law [<i>Lei Geral de Prote\u00e7\u00e3o de Dados<\/i> (LGPD)] were invited to participate in the study. All patients included have signed the Informed Consent Form (ICF). This study was submitted to and approved by the Ethical Committee of Hospital de Cl\u00ednicas de Porto Alegre (CAAE: 54235721.9.0000.5327).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The study was an initiative of the company <i>Produtos Roche Qu\u00edmicos e Farmac\u00eauticos S\/A do Brasil<\/i>. The researchers involved in the study had full autonomy in conducting the study and are responsible for the data presented here.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"159"}}